Gene · 2921
NIH grants2,607
NIH grants whose papers are about the gene, through NIH's grant-paper links.
281 to 300 of 2,607
Download this page as JSON| Grant | Title | CXCL3 papers | Newest fiscal year |
|---|---|---|---|
| R01AR078917 | Understanding the mechanisms by which weight change affects progression of knee osteoarthritis in obese and overweight individuals: An analysis of the Osteoarthritis Initiative Dataset | 1 | 2025 |
| R01AR081640 | Hippo signaling as a critical regulator of lupus keratinocyte dysfunction | 1 | 2025 |
| R01CA114536 | Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy | 1 | 2025 |
| R01CA138833 | New carcinogenic mechanisms of Helicobacter pylori infection | 1 | 2025 |
| R01CA148761 | Therapeutic Targeting of Breast Cancer Tumor Initiating Cells | 1 | 2025 |
| R01CA155010 | Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | 1 | 2025 |
| R01CA173852 | Role of p21 activated kinase in Leukemogenesis | 1 | 2025 |
| R01CA178393 | Genomic Architecture of LGL Leukemia | 1 | 2025 |
| R01CA181745 | Optimizing radiation therapy through the manipulation of glutamine metabolism | 1 | 2025 |
| R01CA193837 | Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependence | 1 | 2025 |
| R01CA197363 | The Tumor Microenvironment Niche of Type I conventional Dendritic Cells | 1 | 2025 |
| R01CA197916 | Targeting the liver for immunotherapy in pancreatic cancer | 1 | 2025 |
| R01CA198887 | MULTIPLEXED PROTEIN BIOMARKER-BASED ASSAY FOR THE DETECTION OF BLADDER CANCER | 1 | 2025 |
| R01CA202919 | Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer | 1 | 2025 |
| R01CA217987 | Metabolic barriers to T cell activation in clear cell renal cell carcinoma | 1 | 2025 |
| R01CA236356 | Protein arginine methylation in breast cancer | 1 | 2025 |
| R01CA241554 | Dysregulated transcription processes in Ewing sarcoma | 1 | 2025 |
| R01CA243142 | Regulation of tumor recurrence by stress activated neutrophils | 1 | 2025 |
| R01CA247862 | Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer | 1 | 2025 |
| R01CA253391 | Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery system | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2921/grants?page=15